Discover how Ergomed successfully recruited 140 patients with Alkaptonuria (AKU)—a rare genetic disorder affecting only 350 known patients in Europe—in just 9 months.
This Phase II/III Repurposing Study, funded by a European FP7 grant, aimed to repurpose drugs for AKU with a focus on long-term patient follow-up.
See how Ergomed collaborated with the AKU Society, developed an extensive online awareness campaign, and organized cross-border enrollment and travel support. Download the full case study to learn how Ergomed’s strategic outreach and patient-centered approach drove recruitment success in ultra-rare disease trials.
